The relation between thyroid status and diseases and cancer is unclear. No detailed analysis of thyroid hormone receptor (TR) expression in human breast cancer has been reported. We have analysed the expression and mutational status of the TRa1, encoded by the c-erbA proto-oncogene, TRb1 and TRb2 isoforms in 70 sporadic breast cancers. Alterations in the RNA level of TRb1, TRa1, or both were found in a number of patients. No expression of TRb2 RNA was detected. Western blotting analysis con®rmed the dierences in expression at the protein level in those cases where sucient tumor sample was available. Additionally, tumor-speci®c truncated TRb1 RNA was found in six patients. Strikingly, three transcripts shared the same breakpoint. Only one tumor carried the corresponding deletion at the genomic DNA level, suggesting that the remaining abnormal TRb1 transcripts are aberrant splicing products. Though no signi®cant correlation was found between TRb1 alteration and any clinical parameter, it showed a tendency to associate with early age of onset (550 years). Our results reveal speci®c alterations in the expression of TRb and TRa genes in a subset of breast cancer patients, suggesting that deregulation of thyroid hormone target genes may be involved in the generation of this neoplasia.
Introduction
Breast cancer is the most common neoplasia and the second cause of cancer deaths in women in western countries (Kelsey and Horm-Ross, 1993; Alberg and Helzlsouer, 1997) . Numerous physiological agents and pathological conditions as well as environmental risk factors have been proposed to in¯uence the development of this neoplasia. Among them, thyroid hormone (triiodothyronine, T3, and its precursor thyroxine, T4) has long been postulated since Beatson described the use of thyroid extracts for metastatic breast cancer treatment more than a century ago (Beatson, 1896) . However, the relation between thyroid status and diseases and the pathogenesis of human breast cancer is not understood (Hedley et al., 1981; Guernsey, 1993; Strain et al., 1997; Smyth, 1997) .
T3 binds to speci®c high anity receptors (TR, thyroid receptors) which belong to the superfamily of nuclear receptors (Mangelsdorf et al., 1995) . They function as ligand-modulated transcription factors regulating the expression of target genes upon binding to speci®c sequences named hormone response elements (MunÄ oz and Bernal, 1997) . TRs are encoded by two genes, TRa and TRb, located on human chromosomes 17 and 3, respectively. By alternative splicing and dierential promoter usage these two genes yield up to nine polypeptides, only four of which bind T3 and are functional receptors: TRa1, TRb1, TRb2, and TRb3 (MunÄ oz and Bernal, 1997; Chassande et al., 1997; Williams, 2000; Dressel and Baniahmad, 2001) . Every cell type in the organism expresses a de®ned pattern of receptor isoforms depending on its developmental and physiological state. Remarkably, the retroviral v-erbA oncogene encoding a mutated TRa1 gene induces erythroleukemia and sarcomas in birds (Sap et al., 1986) and hepatocarcinomas in transgenic mice (Barlow et al., 1994) .
Data on the integrity of TR genes in human breast tumors are very scarce. Two studies reporting allelic losses suggested that TR genes may function as tumor suppressors. In one study TRb gene was located in the 3p21 ± 25 region of somatic homozygosity in breast carcinomas (Ali et al., 1989) . In another study, TRa locus was reported in a region of chromosome 17 lost in 11 out of 14 sporadic breast carcinomas (Futreal et al., 1992) . However, no point mutations were found thus excluding this locus as a common tumor suppressor gene in breast cancer (Futreal et al., 1994) . The validity of these studies has, however, been criticized, since they were based on markers whose location is not mapped precisely (Huber-Gieseke et al., 1997) . Additionally, frequent co-ampli®cation of TRa with the c-erbB2/neu oncogene was reported in human mammary tumors; although overexpression was not detected (van de Vijver et al., 1987) . Little is known about TR expression in human breast cancer patients. Only a few reports have described the presence of uncharacterized TR in breast tumors (Smallridge and Latham, 1980; Cerbon et al., 1981; Alvarado-Pisani et al., 1986) .
Here we analyse the pattern of expression and integrity of the RNA encoding TRa1, TRb1, and TRb2 in human breast cancer. A series of matched samples of tumoral and control tissue from 70 patients with known clinicopathological parameters were analysed by semi-quantitative reverse transcription-polymerase chain reaction (RT ± PCR) and single-stranded conformational polymorphism (SSCP), and those suspected of harboring alterations were sequenced. Several patients showed alterations in TRb1 and TRa1 expression levels that were con®rmed by real-time PCR and Western blotting, while expression of TRb2 was not detected. Expression of truncated TRb1 transcripts were found in six patients. Only one abnormal transcript correlated with a genomic deletion, while the remaining ®ve most probably result from alternative or aberrant splicing events.
Results

TR RNA expression is altered in a subset of breast tumors
We ®rst analysed the pattern of expression of TR genes in normal breast samples by semi-quantitative PCR. Primers used as shown in Table 1 . Both TRa1 and TRb1 were expressed in normal breast tissue ( Figure  1 ). In contrast, no expression of TRb2 RNA was found in any of the 70 samples studied.
Several alterations were found in TRa1 and TRb1 RNA expression in the matched tumor tissues. Six samples displayed changes in TRa1 RNA levels (two up-regulated and four down-regulated), and four in TRb1 RNA (one up-regulated and three downregulated), while two neoplastic tissues displayed concomitant alterations in both (down-regulation of TRb1 and up-or down-regulation of TRa1) ( Figure  2a ). Additionally, six tumor samples, but not their normal counterparts, presented novel TRb1 transcripts, GAA CAG AAG CCA AGC AA  53  1233  A1R  TTA GAC TTC CTG ATC CTC AA  B1F  AATG ACA GAA AAT GGC CTT AC  53  1371  B1R  CTA ATC CTC GAA CAC TTC CA  2B1F  ATG AAC TAC TGT ATG CAA GA  53  1431  B12R  CTA ATC CTC GAA CAC TTC CA  NA1F  AGC AAG GTG GAG TGT GG  51  1203  NA1R  TCC TCA AAG ACC TCG AGG  NB1F  ACA GCT TGG GAC AAA CC  51  1338  NB1R  TTC CAG GAA CAA AGG GG  N2B1F  TAT GAA GTG CAC CCA GC  51  1392  NB1R  TTC CAG GAA CAA AGG GG  b-Actin F  CCA ACC GCG AGA AGA TGA CC  64  414  b-Actin R  TGC CAA TGG TGA TGA CCT GG  TRa1QF  CCCTGAAAACCAGCATGTCAG  68  150  TRa1QR  TTCTTCTGGATTGTGCGGC  TRb1QF  AAGTGCCCAGACCTTCCAAA  68  150  TRb1QR AAAGAAACCCTTGCAGCCTTC b-ActinQF GGCACCACACCTTCTACAATG 68 351 b-ActinQR GTGGTGGTGTAAGCTGTAGCC *A1F, A1R, (TRa), B1F, B1R (TRb1), 2B1F, B1R (TRb2), and b-Actin F, b-Actin R were used for the RT ± PCR, and NA1F, NA1R (TRa), NB1F, NB1R (TRb1), N2B1F and NB1R (TRb2) were used for the nested ampli®cation, in the semiquantitative analysis. TRa1QF, TRa1QR, TRb1QF, TRb1QR, b-ActinQF, and bActinQR, were used in the quantitative study TR protein levels correlate with RNA expression To con®rm at the protein level the dierences in RNA expression found by using semi-quantitative RT ± PCR, we performed Western analysis of the cases where tumor and normal tissues were available, ®ve with normal RNA expression and patients #24 and #76 with altered expression. According to previous reports, a band of 48 kDa was detected using an antibody (a-144) against TRa1, while two dierent anti-TRb antibodies (b-62 and b-82) detected a band of 55 kDa (Falcone et al., 1992) . The results were in good concordance with those obtained by semi-quantitative RT ± PCR: no changes in protein levels were detected in any of the ®ve patients with normal TR RNA expression, while lower expression of TRb1 but not TRa1 polypeptides was found in patient #24, and reduction in both TRa1 and TRb1 was clear in patient #76 (Figure 3 ).
Quantitative PCR analysis confirms alterations in TR RNA expression
We did not have sucient sample to analyse the expression of TR polypeptides in the 12 cases with altered RNA expression, so we performed real-time quantitative PCR in these cases and also in 10 others expressing normal RNA levels. The results were consistent with those obtained by semi-quantitative PCR in 10 out of 12 cases displaying altered TRa1 and/or TRb1 RNA levels, and also in the cases with normal expression (Figure 4 ). However, only minor dierences in expression were found in the two cases in which concomitant alterations in both TRb1 and TRa1 RNAs had been found by semi-quantitative RT ± PCR (not shown). The linear relationship between the fractional cycle and the¯uorescent threshold was strong (r 2 =1).
SSCP analysis suggests the expression of abnormal TR transcripts in breast tumor tissue
Restriction fragments from TRa1 and TRb1 cDNAs obtained from all patients were analysed (Table 2) . Five tumor samples showed a dierential band when compared to matched normal tissue (not shown). Four of the changes in mobility corresponded to TRb1 cDNA fragments, and the remaining to TRa1 cDNA. Three of the tumor samples showing changes in TRb1 cDNA fragments mobility corresponded to those expressing shorter transcripts (patients #12, #22, and #71).
Truncated TRb1 RNAs are expressed in breast tumors
Sequencing of the six selected short TRb1 cDNAs con®rmed the presence of truncations of variable length, ranging from 135 to 705 bp. A scheme of the encoded transcripts with the location of the deletions and the aected domains in the corresponding products is shown in Figure 5 . The aminoterminal A/ B domain responsible for the ligand-independent transactivation activity were not included in any deletion. In one patient (#12) the deletion links G369 with C724 without altering the reading frame. As a consequence, the mutant TRb1 lacked exons 4 and 5 which encode respectively part of the DNA-binding C domain (the second zinc ®nger) and the hinge D domain. Another mutant (#71) had an internal deletion in exon 7 corresponding to part of the heterodimerization and hormone binding E domain, which linked A958 to T1094 and caused the change of Ser320 into an Ile without aecting the reading frame. Remarkably, three patients (#22, #56, and #86) expressed truncated TRb1 RNA which shared nearly the same breakpoint located close to the end of exon 4, a result that may indicate the presence of a fragile site or, alternatively, a cryptic splicing site. These deletions led to the expression of short transcripts encoding only the aminoterminal A/B and C domains. One of mutant transcripts (patient #86) linked T498 to A1024 and restored the wild-type frameshift 120 nucleotides before the stop codon. Though this RNA includes the carboxyterminal AF-2 motif, it is highly improbable that its encoded product can retain transactivating activity since it lacks most of the ligand-binding and heterodimerization domain. The TRb1 transcript of patient #76 was similar to this one but with a smaller deletion linking T542 to T1143. This patient also showed a reduced level of TRa1 RNA. Therefore, at least ®ve of the six mutant TRb1 transcripts encoded severely truncated receptor proteins which, if stably expressed, may be either non-functional or exhibit altered biological activities.
None of the 10 tumor samples which gave bands with normal mobility in SSCP and neither of the other two patients (#10 and #16) with an abnormal SSCP pattern showed any sequence alteration (not shown).
Only one tumor contained a mutation at the TRb1 locus
To explore whether the aberrant TRb1 transcripts resulted from deletions at the DNA level, we attempted to amplify the genomic sequences bearing the putative intragenic TRb deletions by using¯anking primers (Table 3) . These primers were designed in such a way that an ampli®ed PCR product would be expected in the case of a deletion in the genomic DNA, while no such product is expected if the TRb gene is intact due to the very large DNA sequence to be ampli®ed. With the exception of patient #71, no ampli®ed products were obtained (not shown). Subsequent sequencing con®rmed an internal deletion in exon 7 of TRb gene in the tumor sample of patient #71, which was absent in the normal breast tissue. In patient #12, which expressed an abnormal TRb1 transcript lacking exons 4 and 5, we searched by the same method for mutations in the splice acceptor site of exon 4 that could give rise to exon skipping. However, no alterations in the genomic sequence were found.
Clinicopathological correlations
None of the parameters analysed revealed signi®cant association with alterations in TR genes in tumor breast tissue (abnormal expression or deletion). However, four of the six patients with mutated TRb1 were under 50 years of age at diagnosis, while in contrast only 16 of the remaining 64 patients (25%) were diagnosed before this age (P=0.05). The family history of the six patients expressing aberrant TRb1 transcripts was irrelevant with respect to breast cancer, with only one patient (#22) having a second-degree relative aected. 
Discussion
This study shows alterations in TR expression in human breast tumors. Six out of 70 patients expressed truncated TRb1 RNA in tumor but not in control tissue. The reason for the appearance of abnormal TRb1 transcripts was, in one case, a genomic deletion (patient #71) and, in another, could be exon skipping by alternative splicing (patient #12), while in the remaining four cases it is unknown. We speculate that the neoplastic transformation alters the normal splicing mechanism, producing aberrant spliced messengers. Additional point mutations, however, cannot be ruled out given the possibility of false negatives associated with the SSCP technique. We also detected changes in the level of TRb1 and TRa1 RNAs in a number of patients, which were con®rmed at the protein level in those cases where sucient material was available. No signi®cant correlation was found to any clinicopathological parameter, which is not surprising given the size of the series and the percentage of mutations. To our knowledge this is the ®rst description of the expression of altered TR genes in human breast cancer. Abnormalities in TR genes have been described in other human malignancies such as hepatocellular carcinomas, colon, thyroid, lung, pituitary and gastrointestinal tumors (Arbuthnot et al., 1989; Lin et al., 1999; McCabe et al., 1999; Markowitz et al., 1989; Wallin et al., 1992; Dobrovic et al., 1988) . However, none of these studies included a systematic analysis of TRs expression in a substantial number of patients. More recently, TR expression was studied in 20 cases of human renal clear cell carcinoma (Puzianowska-Kuznicka et al., 2000) . While TRa RNA level was decreased, the TRa1 protein was increased in tumors. TRb1 protein was barely detectable even in those (30%) cancers showing TRb RNA overexpression. In a subsequent Figure 5 Schematic representation of the six truncated TRb1 RNA found. The domains and respective functions, and exon pattern in TRb1 are indicated. AF(Activation Function)-1 and -2 are the regions responsible respectively for the hormoneindependent and -dependent transactivation functions of the receptor; the CoR-box is a sequence in the hinge region implicated in transcriptional co-repressor recruitment (Collingwood et al., 1998) ; and the signature motif is a sequence highly conserved among nuclear receptors which has been proposed to stabilize the folding of the receptor molecule and play a role in dimerization and perhaps transcriptional activation and repression (O'Donnell and Koenig, 1990; Busch et al., 1997; Collingwood et al., 1998) . Numbers below the sequences refer to the aminoacids linked in the mutated transcripts. Deleted areas are in large brackets. Dotted lines represent the non-in frame new sequences with numbers of aminoacids in small brackets, and STOP indicates the appearance of abnormal termination codons work, these authors have reported mutations in seven TRb and three TRa RNAs in a series of 22 renal carcinomas (Kamiya et al., 2002) .
Given its complex array of biological activities, a mutated TR can compromise cell growth or the dierentiated phenotype in multiple ways. Conceivably, abnormal TR carrying deletions such as those described here, which mostly aect the carboxyterminal half of the molecule, may inhibit the induction (or repression) of target genes by T3 acting as dominant negative over the normal cellular receptors. Supposedly, except #12 which has a deleted second zinc ®nger, the mutant TRb can bind DNA and so, competitively inhibit the access of co-expressed wildtype receptors to response elements in target promoters. This situation is reminiscent of what happens in patients with the syndrome of generalized thyroid hormone resistance, most of whom carry mutations in the TRb gene that produce non-hormone binding polypeptides with dominant negative activity (Dressel and Baniahmad, 2001) . Moreover, mutated TR may alter other cellular control systems or signaling pathways through an abnormal interaction with their component elements such as p53 or AP-1 (c-Jun, cFos).
The fact that TRb1 in patient #12 lacks exons 4 and 5 suggests an alteration in the splicing of this transcript. Alternatively, this RNA species might be a minor natural splice variant, though the loss of the second zinc ®nger makes this unlikely. The presence of alterations in the splicing of TRb gene in breast tumors is further indicated by the expression of several aberrant transcripts in which the splicing does not occur at de facto splicing sites. The ®nding of a genomic deletion in only one case supports this hypothesis. These results are in line with those recently reported for the mdm2 oncogene in human breast cancer (Lukas et al., 2001) . These authors found both alternative and aberrant mdm2 RNAs in some tumors. Alternative spliced variants of the estrogen receptor-a (ERa) mRNA have also been widely reported (Fasco et al., 2000) , indicating that the splicing process is sometimes altered in this neoplasia. To what extent mutant proteins encoded by splicing variants of these (TRb1, ERa, mdm2) and other RNAs aect the biology of the mammary epithelial cells is unknown. It will probably depend on how the level of expression of each variant modulates the activity of the wild-type protein.
The ®nding of TRb1 and TRa1 RNA expression in all samples analysed is consistent with the proposed action of T3 in the breast, and supports the interest of studies on the eect of this hormone and its receptors in mammary epithelial cells. Also, the lack of TRb2 RNA agrees with the more restricted expression of this isoform (Forrest and VennstroÈ m, 2000, and references therein). Quantitative dierences found in TR RNA expression with respect to normal tissue were never overwhelming, and only in one case was no wild-type TRb1 RNA found. These ®ndings indicate that large deletions covering the whole TR genes are not frequent, and contradict two previous reports suggest- Table 3 Sequence, annealing temperature (Ta), and size of the primers utilized for RTM ± PCR ± SSCP analysis and in the DNA genomic study*. The ®rst three pairs of primers were used for TRa1 ampli®cation and the second three pairs for TRb1 (three set of primers were used in each region to obtain an appropriate size for the SSCP). The last ®ve sets of primers were used in the genomic DNA analysis of the six tumors expressing truncated transcripts, being 12F8 and 22-56R* common for cases #22 and #56 (Ali et al., 1989; Futreal et al., 1992) . Our data do not support the idea that TRb or TRa are tumor suppressor genes. Rather, they indicate that expression of altered TR may contribute to the appearance or progression of breast tumors.
In mouse EpH4 mammary epithelial cells expressing exogenous TRa1, T3 regulates expression of stromelysin-1 and -2, collagenase IVB, and tenascin-C and modulates the dierentiated phenotype (LoÂ pez- Barahona et al., 1995; GonzaÂ lez-Sancho et al., 1999) . TR are also present in human breast cancer cell lines (Burke and McGuire, 1978; Zhou-Li et al., 1992) , but con¯icting reports describe both mitogenic and antimitogenic eects of T3 (Nogueira and Brentani, 1996; MartõÂ nez et al., 2000) . A role of T3 in the physiology of ®brocystic breast disease has been suggested (MartõÂ nez et al., 1995) . Although there is little evidence that overt thyroid disease causes breast cancer, hypothyroidism has been proposed to favor the development of breast cancer by sensitizing breast tissue to the growth promoting action of estrogen, prolactin, and carcinogens (Smyth et al., 1996; Smyth, 1997) . Hypothyroidism or sick euthyroid syndrome are frequently found in cancer patients perhaps as a consequence of an increased level of cytokines such as IL-6 (Yokoe et al., 1997) , and low circulating thyroid hormone has also been associated with poor response to therapy and prognosis (Yokoe et al., 1996) . Normal mammary epithelium expresses TR genes, and is thus sensitive to T3. T3 regulates lobulo-alveolar development, increases prolactin binding, and augments milk production induced by insulin, prolactin and hydrocortisone (Singh and Bern, 1969; Vonderhaar and Greco, 1979; Selliti et al., 1983) , probably by inducing the expression of genes such as a-lactalbumin, casein and epidermal growth factor receptor (Vonderhaar, 1977; Houdebine et al., 1978; Vonderhaar et al., 1986; Hudson et al., 1990) . Strikingly, T3 modulates ER expression and coregulates gene expression with estrogen in non-mammary tissues (Cidlowski and Muldoon, 1975; Zhu et al., 1996) . However data on mammary epithelial cells are lacking. Recently, TRa1, but neither of the TRb isoforms, has been reported to inhibit ERa transactivation from consensus estrogen response element whereas it facilitates ERb-mediated transactivation (Vasudevan et al., 2001a) . However, this interaction on the estrogen response element present in a physiological promoter is dierent (Vasudevan et al., 2001b) . Given that ER and TR also share some transcriptional co-activators and that alterations in expression of some of these such as AIB1 have been reported in breast cancers (Anzick et al., 1997; Bautista et al., 1998) alterations in TR expression may aect estrogen action and breast tumor biology.
In line with the view that the dierent TRs exert only partially redundant eects and act in a tissuespeci®c fashion (Forrest and VennstroÈ m, 2000) , we speculate that the more frequent alteration of TRb1 re¯ects a predominant biological role of this isoform in breast cancer. The speci®city and alterations of TR expression found in our study may help to explain the con¯icting results published on the relation between thyroid status and disease and this neoplasia. Our results indicate the necessity to complement the measurement of blood T3 and T4 concentrations with the analysis of TR expression and integrity. Further studies analysing TR expression at the protein level, and in larger series of patients may establish the signi®cance of the presence of TRb1 variants in breast tumors and its putative correlation with any clinicopathological parameter.
Material and methods
Tumor samples and clinicopathological parameters
Seventy sporadic breast carcinomas and normal breast tissue samples from the same patients were snap-frozen in liquid nitrogen immediately after resection. All tumor samples contained at least 75% tumor cells under histological examination. The following parameters were obtained from the medical records of the 70 patients: birth date, tumor size, lymph node metastases, presence of steroid receptors (estrogen and progesterone), peritumoral vessel involvement, pathologic stage, histological grade, proliferation index, and c-ErbB2 status. Pathological stage was assessed using the tumor-node-metastasis (TNM) classi®cation. All tumors were graded according to the Bloom-Richardson system. Steroid receptor content (estrogen and progesterone), the proliferative index and the c-ErbB2 expression were determined by immunohistochemical procedures.
RNA extraction and semi-quantitative RT ± PCR
Total RNA was isolated from frozen tumor tissues of breast carcinomas, matched with normal healthy breast tissue, using RNeasy Mini Kit (Qiagen Inc., Hilden, Germany), and quanti®ed spectrophotometrically. Thirty ng of total RNA was reverse-transcribed into ®rst strand cDNA and ampli®ed in one step using the Gold RNA PCR Core Kit (PE Biosystems) according to the manufacturer's protocol. The annealing temperature was 538C for the three cDNAs and the elongation time was 105 s. The ®nal volume was 20 ml and 40 cycles of ampli®cation were used. We used b-actin as control in the same conditions but the annealing temperature was 648C instead of 538C, and the number of cycles was 35 instead of 40 (Table 1) . In order to increase the weak signal of the three TR genes, we performed a second, nested PCR ampli®cation using a distinct set of primers (Table 1) . To this, 3 ml of the product of the ®rst PCR was re-ampli®ed in a ®nal volume of 25 ml, the annealing temperature was 51 ± 568C (depending on the set of primers, see Table 1 ). The loglinear phase, used for semi-quantitative analysis, was established at 32 cycles for TRa1 and at 35 cycles for TRb1 (Figure 1 ) (Corral-Debrinski et al., 1992; Ballinger et al., 1996) . In these conditions the ampli®cation showed linearity, as shown by serial dilutions. No signal was found for TRb2. Nested-ampli®ed products were analysed as described above. Gel images were captured using a GS-690 Imaging Densitometer (Bio-Rad Laboratories, Hercules, CA, U.S.A.), digitized in 400 d.p.i., and analysed using MultiAnalyst/PC (Bio-Rad laboratories). TR genes expression was calculated as the expression ratio of tumor to normal tissue after normalization to the corresponding b-actin levels. The log-linear phase was established at 30 cycles for b-actin. High TR expression was arbitrarily de®ned as a fourfold or higher increase over that of normal tissue, while reduced expression was considered when the value was 25% or less. Semiquantitative RT ± PCR from tumors and their matched normal tissues was done three times to ensure reproducibility of the results. Two additional TRb isoforms generated by alternative splicing, TRb3 and TRbD3, have been described (Williams, 2000) . TRb3 and TRbD3 RNAs have dierent 5'-sequences from TRb1 and TRb2, which excludes the possibility of their ampli®cation in the conditions used in our study.
Quantitative PCR
Real-time quantitative PCR were performed using a LightCycler apparatus (Roche Diagnostics, Mannheim, Germany) using the LightCycler-FastStart DNA Master SYBR Green I Kit (Roche Diagnostics). Each reaction was done in a ®nal volume of 20 ml containing 2 ml of cDNA sample, 4 mM MgCl 2 , 0.5 mM of each primer as well as 16reaction mix including FastStart DNA polymerase, reaction buer, dNTPs and SYBR green. PCR conditions were: 6 min at 958C and 40 cycles of 958C for 20 s, 688C for 30 s and 728C for 15 s. The expression levels of TRa1 and TRb1 were normalized to that of b-actin. A diluted sample of normal tissue was used to perform the standard curves for TRa1 and TRb1. The primers used were designed with the assistance of the Primer Express TM 1.5 program (PE Applied Biosystems) ( Table 1) .
Western blotting
Protein extracts from tissue samples were obtained by homogenization using the Dignam C buer supplemented with 1% NP40 and protease inhibitors as described (GonzaÂ lez et al., 2000) followed by 30 min incubation on ice and centrifugation at 10 000 g at 48C for 10 min. Aliquots of the supernatants containing 40 mg protein were electrophoresed in 12% polyacrylamide gels and transferred to nylon PVDF membranes using a vertical BioRad transfer apparatus at 1 mA/cm 2 overnight. Equal loading of individual extracts was ensured by measuring protein concentration using the Bio-Rad Protein Assay. The ®lters were washed, blocked with TBS (20 mM Tris base, 137 mM Na Cl) pH 7.6, 0.1% Tween 20, 3% BSA, and incubated overnight at 48C with the following anti-human TR antibodies (generously donated by Prof. L DeGroot, Chicago): a-144, recognizing TRa (1 : 200 dilution) and b-62 and b-82 (1 : 200 dilution), recognizing TRb1 and TRb2. As control we used an anti-histone antibody (Boehringer Mannheim 1492-519, 1 : 1000 dilution). Blots were washed 3615 min with TBS, 0.1% Tween-20 and incubated with a horse anti-rabbit peroxidase secondary antibody (1 : 10.000; Sigma) for 1 h at room temperature. The blots were developed by a peroxidase reaction using the Luminol detection system (Pierce).
Single-stranded conformational polymorphism (SSCP)
Three fragments of each gene, TRa1 and TRb1, were ampli®ed using annealing temperatures that varied depending on the pair primers (Table 3) . PCR was performed under the same conditions aforementioned using as template 3 ml from the ®rst PCR product. Ampli®ed products were incubated with restriction enzymes as indicated (Table 2 ) in order to obtain several fragments of appropriate sizes for SSCP analysis. We followed the manufacturer's procedure (New England Biolab, Inc.) including two modi®cations to ensure a complete digestion: (i) three times higher restriction enzymes concentrations, and (ii) overnight incubation. Complete digestion of all samples was checked by electrophoresis in 8% polyacrylamide gels for 3 h at 400 V. The digested samples (10 ml) were denatured by mixing with 15 ml of denaturing stop solution (98% formamide, 0.02% xylene cyanol, and 0.02% bromophenol blue), heated to 958C for 5 min, and cooled on ice. Samples were analysed on nondenaturing 10% polyacrylamide gels run for 12 ± 15 h at 250 V, and stained by the silver staining method.
DNA sequencing
Tumor samples showing RNA of unexpected sizes during the expression analysis were subjected to PCR, and the ampli®ed material was run in 1% low melting point agarose gels for 2 h at 80 V. cDNAs of unusual size were puri®ed using the DNA and Gel Band Puri®cation Kit (Amersham Biotech Inc.). Likewise, specimens that showed a dierential band at SSCP were reampli®ed and PCR products were puri®ed using the High Pure PCR Product Puri®cation Kit (Boehringer Mannheim Corp., USA). Both types of puri®ed DNA fragments were sequenced using an ABI Prism TM 377 DNA Sequencer apparatus (PE Applied Biosystem). To rule out false negative 10 tumor samples without abnormal SSCP pattern were also sequenced.
Statistical analysis
The variables analysed were contrasted using the w 2 test, the w 2 test with the Yates correction (Armitage and Berry, 1987) , or Fisher's exact test when any of the expected frequencies was less than ®ve. Two-tailed P values of 50.05 were considered statistically signi®cant. Statistical analyses were performed using the EPI ± INFO package, version 6.04.
